Effects of lorazepam on hyperactivity in ratarded children

Seven mentally-retarded children, diagnosed as hyperactive, participated in a double-blind trial of the drug lorazepam (Ativan). Statistical analysis of the behavioural records showed that hyperactivity was typically greater during lorazepam than during placebo periods. The degree of hyperactivity was not systematically related to dosage level. The drug is therefore contraindicated for the control of hyperactivity in mentally retarded children.